In the study of Ronchetti et al., the power of the “2-lncRNA risk model” to predict TTFT was independent of the Progression–Risk Score, which integrates clinical and genetic variables similar to CLL-IPI (Rai stage, absolute lymphocyte count, serum β2-microglobulin and IGHV SHM status) [31,72]. The gene discussed is HLA-G; the disease is B-cell chronic lymphocytic leukemia.